Navigation Links
Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Date:11/20/2013

; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends. These and other important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts: 

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
2. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
3. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
4. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
7. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
8. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
9. Aratana Therapeutics Completes $15 Million Series B Financing
10. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
11. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Intrexon Corporation ... first quarter 2015 financial results after the market closes ... conference call that day at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Conference Call."  Participants may also ...
(Date:5/1/2015)... OncoTAb, Inc., a University of North ... Pinku Mukherjee, Ph.D. has received the O. Max ... faculty honor. Mukherjee received the award, which recognizes ... research and development of cancer diagnostics and treatments. , ... in my scientific career,” said Mukherjee, OncoTAb Co-founder and ...
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... ) announced today that Roger Jeffs , Ph.D., President ... overview and update on the company,s business at the Deutsche ... Boston, Massachusetts . The presentation will ... Eastern Time, and can be accessed via a live webcast ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Middle East,s only forum for the global pharma/biotech industries, Pharmaceutical Manufacturing ... ... April 2008, DUBAI, United Arab Emirates, Sept. 4 The Middle ... and with annual growth in double digits. The market,drivers are: -- ...
... Exists Between Understanding Cholesterol Monitoring Versus ... N.J., Sept. 4, 2007 A recent survey ... spite of concerns about the,serious health risks associated ... coronary heart disease, there is a significant disconnect,between ...
... Calif., Sept. 4 Volcano,Corporation (Nasdaq: VOLC ... measurement (FM) products designed to enhance the diagnosis,and ... today that it,will be participating in the Bear ... The presentation by Scott Huennekens, president and chief ...
Cached Biology Technology:New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 2New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 3New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 4New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 5New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 6New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 7Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... French . , Two McGill researchers have ... Fellowships. Dr. Andrew P. Hendry an associate professor with ... Dr. Karim Nader, an associate professor and Willam Dawson ... the prestigious fellowships from the Natural Sciences and Engineering ...
... emotional toll on our bodies and scientists are working on ... to stress at the cellular level in the brain. ... essential for survival. Using a rat model, Jaideep ... of researchers at the Hotchkiss Brain Institute have discovered that ...
... for pregnant women and their children, and vitamin B12 ... any common multivitamin, say doctors and dietitians with the ... are available for comment in response to a new ... vitamin B12 may increase the risk for neural tube ...
Cached Biology News:2 McGill researchers garner prestigious NSERC Steacie Fellowships 2New and unexpected mechanism identified how the brain responds to stress 2Doctors endorse vegan and vegetarian diets for healthy pregnancies 2